ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $63K of NXTC (indirect holdings)
ADAR1 Capital Management, LLC purchased 12,333 indirectly-held shares of NextCure, Inc. (NXTC) at $5.10 on 2026-11-11. Filed jointly with Schneeberger Daniel (10% owner).
How this was made
The 30-second read
Why it matters
The filing provides the first public disclosure of a new insider stake increase, offering a modest data point for traders monitoring insider sentiment.
Market read
A small insider purchase by a major shareholder, modestly bullish but limited trading relevance.
What to watch
Potential upcoming clinical data could be the real driver, not the insider trade.
Background
NextCure is a clinical-stage biotech focused on immuno-oncology therapies.
Ticker impact
Form 4 disclosed ADAR1 Capital Management purchased 12,333 shares of NextCure at $5.0999, increasing its stake to 750,289 shares.
slight upward pressure as market prices in insider confidence
The transaction size (~$63K) is modest; however, the buyer is a significant shareholder, which could modestly support the stock.
Market effects
Minimal effect on biotech sector; typical insider activity.
None
Low
Counterpoint
The purchase may be routine portfolio rebalancing, not a bullish signal.
Key entities
- companyNextCure, Inc.
Biotech issuer of the disclosed shares.
- investorADAR1 Capital Management, LLC
Entity making the insider purchase.
